1. Home
  2. EAT vs DFTX Comparison

EAT vs DFTX Comparison

Compare EAT & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brinker International Inc.

EAT

Brinker International Inc.

HOLD

Current Price

$177.39

Market Cap

7.2B

ML Signal

HOLD

Logo Definium Therapeutics Inc. Common Shares

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$43.94

Market Cap

5.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
EAT
DFTX
Founded
1975
N/A
Country
United States
United States
Employees
N/A
106
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
5.9B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
EAT
DFTX
Price
$177.39
$43.94
Analyst Decision
Buy
Strong Buy
Analyst Count
21
8
Target Price
$183.00
$38.50
AVG Volume (30 Days)
909.3K
4.7M
Earning Date
04-29-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
144.71
N/A
EPS
7.90
N/A
Revenue
$5,384,200,000.00
N/A
Revenue This Year
$9.00
N/A
Revenue Next Year
$5.49
N/A
P/E Ratio
$22.49
N/A
Revenue Growth
21.95
N/A
52 Week Low
$100.30
$14.62
52 Week High
$178.25
$49.20

Technical Indicators

Market Signals
Indicator
EAT
DFTX
Relative Strength Index (RSI) 70.06 76.29
Support Level $128.82 $17.51
Resistance Level N/A N/A
Average True Range (ATR) 6.85 2.84
MACD 1.13 1.46
Stochastic Oscillator 97.99 80.53

Price Performance

Historical Comparison
EAT
DFTX

About EAT Brinker International Inc.

Brinker International Inc operates casual dining restaurants under the brand's Chili Grill and Bar (Chili's) and Maggiano's Little Italy (Maggiano's). Chili's falls in the Bar and Grill category of casual dining. Its menu features Fresh Mex and Fresh Tex favorites including signature items such as slow-smoked baby back ribs, craft burgers, fajitas, and bottomless chips and salsa paired with tableside guacamole. Maggiano's is an Italian restaurant brand with a full lunch and dinner menu offering chef-prepared, such as appetizers, chicken, seafood, veal and prime steaks, and desserts. The company generates maximum revenue from Chili's segment.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Share on Social Networks: